[Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
D000328:Adult; D000368:Aged; D001545:Benserazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D002262:Carboxy-Lyases; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D002214:Capsules; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Tratamiento del síndrome de Parkinson con L-dopa y un inhibidor de la decarboxilasa